Y Intercept Hong Kong Ltd Invests $528,000 in Replimune Group, Inc. $REPL

Y Intercept Hong Kong Ltd bought a new stake in Replimune Group, Inc. (NASDAQ:REPL) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 68,978 shares of the company’s stock, valued at approximately $528,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Replimune Group as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of REPL. SG Americas Securities LLC boosted its holdings in Replimune Group by 110.8% in the 1st quarter. SG Americas Securities LLC now owns 151,674 shares of the company’s stock worth $1,160,000 after acquiring an additional 79,719 shares during the period. Invesco Ltd. grew its position in Replimune Group by 297.3% in the fourth quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock valued at $5,959,000 after acquiring an additional 458,714 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Replimune Group during the fourth quarter valued at approximately $322,000. Virtus Investment Advisers LLC raised its stake in shares of Replimune Group by 127.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock valued at $254,000 after purchasing an additional 14,622 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in shares of Replimune Group during the fourth quarter worth $1,058,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REPL has been the subject of a number of recent analyst reports. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 2nd. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, April 10th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.12.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Replimune Group Stock Performance

Replimune Group stock opened at $9.94 on Tuesday. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $13.24. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market cap of $834.36 million, a P/E ratio of -2.94 and a beta of 0.86. The stock has a 50 day moving average of $8.17 and a 200-day moving average of $7.38.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, analysts expect that Replimune Group, Inc. will post -2.29 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.